DNA Methylation Signatures Predicting Bevacizumab Efficacy in Metastatic Breast Cancer

Gampenrieder, SP; Rinnerthaler, G; Hackl, H; Pulverer, W; Weinhaeusel, A; Ilic, S; Hufnagl, C; Hauser-Kronberger, C; Egle, A; Risch, A; Greil, R THERANOSTICS. 2018; 8(8): 2278-2288.

ASCO 2018 highlights: metastatic breast cancer

Rinnerthaler, G; Gampenrieder, SP; Greil, R MEMO-MAG EUR MED ONC. 2018; 11(4): 276-279.

Nonmetastatic pancreatic cancer : Improved survival with chemoradiotherapy > 40 Gy after systemic treatment.

Bachmayer, S; Fastner, G; Vaszi, A; Iglseder, W; Kopp, P; Holzinger, J; Dinnewitzer, A; Rinnerthaler, G; Gampenrieder, SP; Emmanuel, K; Greil, R; Sedlmayer, F; Zehentmayr, F; Strahlenther Onkol. 2018; 194(7): 627-637.

PET-Guided Treatment of Early-Stage Favorable Hodgkin Lymphoma: Final Results of the International, Randomized Phase 3 Trial HD16 by the GHSG

Eich, HT; Baues, C; Fuchs, M; Kobe, C; Greil, R; Sasse, S; Zijlstra, JM; Lohri, A; Rosenwald, A; Tresckow, BV; Diehl, V; Kuhnert, G; Dietlein, M; Borchmann, P; Engert, A INT J RADIAT ONCOL. 2019; 105(1): S1-S1.

A randomized, double-blinded, placebo-controlled multicenter phase II trial of adjuvant immunotherapy with tecemotide (L-BLP25) after R0/R1 hepatic colorectal cancer metastasectomy (LICC): Final results.

Schimanski, CC; Kasper, S; Hegewisch-Becker, S; Schroeder, J; Overkamp, F; Kullmann, F; Bechstein, WO; Voehringer, M; Oellinger, R; Lordick, F; Heinemann, V; Geissler, M; Schulz-Abelius, A; Linz, B; Bernhard, H; Schoen, MR; Greil, R; Smith-Machnow, V; Schmidtmann, I; Moehler, MH J CLIN ONCOL. 2019; 37(15):

Antihormones with or without irradiation in breast cancer: 10-year results of the ABCSG 8A trial

Fastner, G; Sedlmayer, F; Widder, J; Metz, M; Geinitz, H; Kapp, K; Solkner, L; Greil, R; Jakesz, R; Kwasny, W; Heck, D; Bjelic-Radisic, V; Balic, M; Stoger, H; Wieder, U; Zwrtek, R; Semmler, D; Horvath, W; Melbinger-Zeinitzer, E; Wiesholzer, M; Wette, V; Gnant, M RADIOTHER ONCOL. 2019; 133: S132-S133.

Induction chemotherapy with docetaxel, cisplatin and cetuximab versus docetaxel, cisplatin and 5-fluorouracil followed by radiotherapy with cetuximab for locally advanced or inoperable squamous cell carcinoma of the head and neck: Promising results of a randomized phase II AGMT-trial.

Keil, F; Hartl, M; Altorjai, G; Pecherstorfer, M; Mayrbaurl, B; de Vries, A; Berghold, A; Riedl, R; Fridrik, MA; Fuereder, T; Burian, M; Greil, R J CLIN ONCOL. 2019; 37(15):

Safety and efficacy of PD-L1 inhibitor durvalumab with R-CHOP or R-2-CHOP in subjects with previously untreated, high-risk DLBCL.

Nowakowski, GS; Willenbacher, W; Greil, R; Larsen, TS; Patel, K; Jager, U; Manges, RF; Trumper, LH; Haioun, C; Everaus, H; Kalakonda, N; Knoble, J; Brown, P; Joergensen, JM; Cunningham, D; Domper, N; Casadebaig, ML; Manzke, O; Munoz, J J CLIN ONCOL. 2019; 37(15):

Treatment with 5-Azacytidine results in expression of long terminal repeat (LTR) elements in peripheral blood mononuclear cells of patients with MDS and AML: first pilot study

Daskalakis, M; Haubitz, M; Steiner, D; Helf, M; Brocks, D; Pleyer, L; Greil, R; Plass, C; Baerlocher, GM; Leibundgut, EO SWISS MED WKLY. 2019; 149: 22S-22S.

Prediction of distant recurrence using EndoPredict among women with ER-positive, HER2-negative breast cancer with a maximum follow-up of 16 years

Filipits, M; Dubsky, P; Rudas, M; Greil, R; Balic, M; Fitzal, F; Bago-Horvath, Z; Singer, C; Hlauschek, D; Kronenwett, R; Bernhisel, R; Lancaster, J; Gnant, M CANCER RES. 2019; 79(4):